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Abstract: The RAS/MAP kinase and the RAS/PI3K/AKT pathways play a key role in the
regulation of proliferation, differentiation and survival. The induction of these pathways
depends on Receptor Tyrosine Kinases (RTKs) that are activated upon ligand binding. In
cancer, constitutive and aberrant activations of components of those pathways result in
increased proliferation, survival and metastasis. For instance, mutations affecting RTKs,
Ras, B-Raf, PI3K and AKT are common in perpetuating the malignancy of several types
of cancers and from different tissue origins. Therefore, these signaling pathways became
prime targets for cancer therapy. This review aims to provide an overview about the most
frequently encountered mutations, the pathogenesis that results from such mutations and the
known therapeutic strategies developed to counteract their aberrant functions.
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1. Introduction
Receptor tyrosine kinases (RTKs) are a family of cell surface receptors, which act as receptors
for growth factors, hormones, cytokines, neurotrophic factors and other extracellular signaling
molecules. RTKs mediate key signaling pathways that are involved in cell proliferation, differentiation,
survival and cell migration [1]. The RTK family comprises several subfamilies which include,
among others, epidermal growth factor receptors (EGFRs), fibroblast growth factor receptors
(FGFRs), insulin and insulin-like growth factor receptors (IR and IGFR), platelet-derived growth
factor receptors (PDGFRs), vascular endothelial growth factor receptors (VEGFRs), hepatocyte
growth factor receptors (HGFRs), and proto-oncogene c-KIT [2,3]. RTKs monomers are organized
into an extracellular (N-terminal), a transmembrane and a cytoplasmic kinase domain. They are
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activated via ligand-induced dimerization that results in receptor auto-phosphorylation and tyrosine
activation of RTKs’ substrates including phospholipase C-γ, mitogen-activated protein kinases and
phosphatidylinositol 3-kinase [4–6] (Figure 1).
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Figure 1. Schematic representation of Receptor Tyrosine Kinase and downstream signaling 
pathways. Receptor Tyrosine Kinases are auto-phosphorylated upon ligand binding, which 
results in the activation of Ras and induction of serine/threonine kinase Raf. Raf 
phosphorylates Mek1/2 which in turn phosphorylate and activate Erk1/2. Raf also activates 
MAP3 kinases that activate MKK4/7, MKKK3/6 and MEK5, which activates JNK1/2, p38 
and ERK5, consecutively. MAP3Ks are also activated by inflammatory cytokines, oxidative 
stress and UV radiation. PI3K is activated by RTK autophosphorylation and results in the 
activation of Akt which also induces mTOR within the mTORC1 complex. Akt is also 
regulated by mTORC2 complex. PLCγ activation leads to Ca+2 mobilization and to the 
activation of PKC. These events play an essential role in proliferation, differentiation, 
survival and cell migration. 
Mutations that affect RTK signaling often lead to cell transformation, which is observed in a wide 
variety of malignancies. These mutations affect RTKs or components of downstream pathways such as 
MAP kinase and the PI3K/AKT. This results in increased cell proliferation, survival, invasion and 
metastasis. Therefore, targeting RTK signaling pathways remains a challenge for scientists and clinicians 
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working in the cancer field. Several small molecule inhibitors and antibodies are being clinically
developed to target RTKs, the MAP kinase and PI3K/AKT pathways. This review attempts to highlight
the important role played by RTK signaling in carcinogenesis and the therapeutic strategies available, so
far, to target these important cellular pathways.
2. Receptor Tyrosine Kinase Signaling and Cancer
2.1. Targeting Receptor Tyrosine Kinases (RTKs) in Cancer
Most RTKs are found mutated in a variety of cancers and from different tissue origins. This chapter
discusses the role of RTKs in cancer and the therapeutic strategies developed to target them (Figure 2
and Table 1).
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the tyrosine kinase domain of RTK, preventing receptors’ auto-phosphorylation and 
inhibiting signal transduction. 
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Table 1. Examples of RTK targeted molecular cancer therapies being used clinically or
subjected to clinical trials.
Target Compound Cancer References
EGFR family
HER2
Trastuzumab
(Herceptin)
HER2-positive breast cancer [7–9]
EGFR Cetuximab (Erbitux)
Metastatic colorectal cancer
(RAS wild type)
Metastatic non-small-cell lung cancer
[10]
Panitumumab
(Vectibix)
[10–12]
Gefitinib (Iressa) [13–15]
Erlotinib (Tarceva) [13,16]
EGFR and HER2 Lapatinib (Tykerb) HER2-positive breast cancer
(Trastuzumab-resistant)
[14,17]
Afatinib NSCLC
HER2-positive breast cancer
[18–21]
VEGFR Sorafenib (Nexavar) Renal, liver and thyroid cancer [22–24]
Sunitinib (Sutent) Renal cell cancer
Gastrointestinal stromal tumor (GIST)
[25,26]
Bevacizumab
(Avastin)
Metastatic colorectal carcinoma [27]
PDGFR Imatinib (Gleevec) GIST (KIT+) [28]
PDGFR and VEGFR Sunitinib Angiogenesis [29–32]
Soratinib
Pazopanib
Nilotinib
FGFR and VEGFR
Brivanib
(BMS-540215)
Human hepatocellular carcinoma
model
[33]
VEGFR, PDGFR,
FLT-3, c-KIT and
FGFR
CHIR-258 (TKI-258) Multiple myelomas [34,35]
MET SGX523
MDCK and A549 cells and GTL16
xenograft models
[36]
C-KIT Imatinib (Gleevec) GIST [37–39]
2.1.1. EGFR-Targeted Therapy
Gene mutations affecting EGFR members have been associated with several cancers [40]. In breast
cancer, overexpression of HER2 (ERBB2) is found in approximately 10%–30% of patients and is
associated with reduced survival [41]. Mutations affecting EGFR gene result in its overexpression
in 30%–50% of glioblastomas [42,43], 25%–82% in colorectal cancer [44–47] and 5%–20% in
non-small-cell lung cancer [13,48]. Therefore, molecular targeted therapeutics were developed against
those receptors. Trastuzumab (Herceptin), a monoclonal antibody, is used to target the extracellular
domain of the HER2 protein in HER2-positive breast cancer patients and has been shown to increase
survival at early and late stages of breast cancer [7]. Cetuximab (Erbitux) and Panitumumab (Vectibix)
are two other examples of monoclonal antibodies that are used to target the EGFR-ligand binding
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in the treatment of patients with metastatic colorectal cancer [11,12]. The benefit of cetuximab and
Panitumumab was limited to patients with RAS wild-type tumors [10].
Lapatinib (Tykerb), a tyrosine kinase inhibitor, targets the ATP binding pocket of the kinase domain
of EGFR and HER2 and has been used as an alternative treatment of HER2-positive breast cancer
patients that developed resistance to Trastuzumab [8,9]. It has also been used in combination with
chemotherapeutic compounds such as Capecitabine, and has been shown to reduce the risk of disease
progression in women with advanced HER2-positive breast cancer who had received multiple previous
treatments [17]. More recently, Lapatinib has been used in combination with letrozole (Femara) to treat
postmenopausal women with Hormone receptor (HR) positive, HER2-positive metastatic breast cancer.
This combination resulted in increased progression free survival in the HER2-positive population [14].
Gefitinib (Iressa) and Erlotinib (Tarceva), which are also tyrosine kinase inhibitors, have been used
in treatment of patients with metastatic non-small-cell lung cancer. These drugs have been used in
combination with chemotherapy and resulted in an improved and progression-free survivals [15,16].
Finally, Afatinib (Giotrif) is a novel ErbB family blocker that selectively blocks ErbB family members
(EFGR, HER2, ErbB4 and ErbB3). Unlike Gefitinib and Erlotinib, Afatinib irreversibly (covalently)
binds to proteins of ErbB family members and blocks their signaling pathways, thus promoting a
sustained anti-proliferative activity [18,19]. This drug has been tested in several clinical trials and has
been shown to extend progression free survival of patients with non-small cell lung carcinoma (NSCLC).
However, this effect appears to be more beneficial to patients carrying EGFR del19 mutations [20].
Furthermore, and as Afatinib targets HER2, it is also being investigated for use in other HER2-positive
cancers such as HER2-positive breast cancer [21].
2.1.2. VEGFR-Targeted Therapy
This family of receptors, which binds VEGF, plays a key role in vasculogenesis and angiogenesis and
is critical to tumor-induced new vascular formation [49]. Several studies have reported elevated levels of
VEGFR in several cancers and these correlated with metastasis and poor prognosis [50–52]. A number of
VEGFR inhibitors have been developed with the aim of reducing angiogenesis and lymphangiogenesis
associated with cancer progression [49]. Sorafenib (Nexavar), a small molecule inhibitor of tyrosine
protein kinase, has been used for the treatment of renal cell, liver and thyroid cancers. An improved
progression-free survival following Sorafenib treatment was reported in patients with advanced renal
cell cancer and nonresponsive thyroid cancer [22,23]. In patients with liver cancer, an improvement of
median overall survival was reported [24]. Sunitinib (Sutent, SU11248) is another VEGFR protein
tyrosine kinase inhibitor, which has been shown to improve overall survival of patients with renal
cell cancer and gastrointestinal stromal tumor [25,26]. Besides the use of small molecule inhibitors
to target VEGFR, a monoclonal antibody (Bevacizumab, Avastin) has been used in combination with
chemotherapy to treat patients with metastatic colorectal carcinoma. This resulted in improvement of
patients’ survival [27].
2.1.3. PDGFR-Targeted Therapy
PDGF and PDGFRs have important functions in the regulation of cell growth and survival. Mutations
within PDGFRα gene have been found in 5% of gastrointestinal stromal cancer (GIST). These mutations
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affect tyrosine kinase domains and juxtamembrane domain [53]. PDGFR genes were also involved in
gene rearrangements found in certain leukemias [54]. In addition, amplifications of PDGFRα were
reported in 5%–10% of glioblastoma multiforme, in oligodendrocytoma, esophageal squamous cell
carcinoma and artery intimal sarcomas [55–60]. As for other dysfunctional RTKs, tyrosine kinase
inhibitors have been developed to target directly PDGFR or as a secondary target. These small
molecule inhibitors include imatinib, sunitinib, sorafenib, pazopanib and nilotinib. Imatinib (Gleevec),
a well-known inhibitor of the oncogenic Bcr-abl fusion protein responsible for chronic myelogenous
leukemia (CML), has been used to target PDGFR in gastrointestinal stromal tumors KIT positive.
Although this treatment led to significant improvement of overall survival, many patients developed
resistance to imatinib [28]. Other drugs such as sunitinib, soratinib, pazopanib and nilotinib were used
to target multiple RTK receptors (e.g., PDGFR and VGFR) with the aim of inhibiting cell proliferation
and angiogenesis to ensure maximum shrinkage of the tumor [29–32].
2.1.4. FGFR-Targeted Therapy
Several mutations affecting FGFR genes have been reported in the literature [61]. Amplifications of
FGFR1 and 2 have been found in breast cancer [62–70] and in gastric cancer where these mutations
were associated with poor prognosis [71,72]. FGFR1 amplifications were found in bladder cancer,
oral squamous carcinoma and ovarian cancer [73–75]. Point mutations that affect FGFR1, 2 and 3
lead to the increase of receptors or constitutive activations and were observed in cancer of the prostate,
bladder, breast, brain, lung, uterus, stomach, head and neck, colon and malignant melanoma [76–86].
Chromosomal translocations involving FGFR genes generate oncogenic protein fusions that are present
in several hematopoietic malignancies such as multiple myelomas and myeloproliferative disorder
syndrome [87–92]. Although several small molecule inhibitors of the FGFR tyrosine kinase are
currently in clinical development, these molecules also target other RTKs such as VEGFR, PDGFR
and c-Kit [33–35,93–99]. Examples of these inhibitors include Brivanib (BMS-540215), a dual
effect inhibitor of FGFR and VEGFR that has been shown to affect tumor growth in mouse models
of human hepatocellular carcinoma (HCC) [33]. CHIR-258 (TKI-258), a multiple target inhibitor
(VEGFR, PDGFR, FLT-3, c-Kit and FGFR), is an effective inhibitor of multiple myelomas harboring
the translocation t (4, 14) (p16; q32) that expresses wild type or activated FGFR3 [34,35].
2.1.5. MET-Targeted Therapy
MET is the receptor for the hepatocyte growth factor and is involved in cell growth, migration,
invasion, metastasis and angiogenesis [100,101]. MET mutations and amplifications have been
reported in many cancers such as neuroblastoma, glioblastomas, osteosarcomas, oesophageal and gastric
colorectal cancers, multiple myelomas and T-cell leukemia. These alterations have been shown to be a
driver of proliferation, invasion and metastasis and are associated with aggressive phenotype and poor
prognosis [102–112]. Since the generation of the first c-MET inhibitor K252a [113], several inhibitors
of MET have been tested clinically [114,115]. Among these inhibitors, SGX523 is a highly specific
inhibitor of MET and has been shown to inhibit the growth of MDCK and A549 cells and GTL16
xenografts [36]. ARQ197 (ArQule) is also a MET-specific inhibitor that has been shown to inhibit the
growth of the breast cancer cell line MDA-MB-231, the prostate cancer cell line PC3, the colon cancer
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cell line HT29 and the pancreatic cancer cell line PaCa2 [116,117]. Other inhibitors have a Broad
spectrum kinase inhibitor effect such as MP470 which acts on MET, RET, KIT, PDGFR and FLT3 or
XL880 and PF2341066 that act on VEGFR2 and ALK, respectively [114].
2.1.6. c-KIT-Targeted Therapy
c-Kit also known as CD117 or Mast/Stem Cell Growth Factor Receptor is a cell surface receptor of
SCF (Stem Cell Factor). C-Kit activation by SCF initiates the activation of downstream pathways that
are involved in the regulation of multiple cellular processes such as proliferation, survival, cell migration,
hematopoiesis, stem cell maintenance, melanogenesis and gametogenesis. Mutations in c-KIT result in
SCF-independent activation of downstream signaling pathways associated with increased proliferation
and cell survival, mostly found in leukemia, gastrointestinal stromal tumors (GIST), testicular germ
cell tumor (TGCT) and melanoma. The majority of oncogenic c-Kit mutations are located in the
juxtamembrane region (e.g., c-KitV560G) or within the kinase domain (e.g., c-KitD816V) [118]. The
tyrosine kinase inhibitor Imatinib (Gleevec), a well-known inhibitor of the oncogenic Bcr-abl fusion
protein, has been used to target the juxtamembrane domain of c-KIT in GIST patients. However,
secondary mutations occur in other parts of the receptor (such as exon 17) that renders the tyrosine kinase
resistant to the inhibition of imatinib [37,38,119]. Although newer c-Kit drugs have been developed
(dasatinib and PKC412) to overcome the resistance to imatinib, these drugs have made little impact.
This is mainly due to the lack of well-validated inhibitors of the forms of KIT that carry certain types
of mutations [39].
2.2. The RAS/MAP Kinase Pathway
This pathway is a central player for a multitude of physiological and pathological cellular processes
such as growth, proliferation, differentiation, migration and apoptosis [120]. Its activation by RTKs
triggers a cascade of phosphorylation involving downstream kinases which leads to the phosphorylation
of target proteins in the nucleus and cytoplasm. The first part of the cascade relies on the activation of
at least one of the four major MAP kinases: ERK1 and 2 (ERK1/2), ERK5, p38, and JNK. ERK1 and
2 are probably the most studied MAP kinases. Receptor tyrosine kinases frequently engage Erk1/2 by
recruiting the RAS guanine exchange factor Sos to the plasma membrane. This factor is constitutively
associated with the protein adapter Grb2, which brings Sos in close proximity to the small GTPase
RAS resulting in a nucleotide exchange from GDP to GTP, a change of Ras protein conformation and
activation of the serine/threonine kinase Raf. The next step involves Raf phosphorylation of Mek1/2
which in turn phosphorylate and activate Erk1/2 [121] (Figure 1).
The ERK5 pathway is the least studied pathway among the MAP kinase pathways. However, its
emerging role as an important player in the regulation of tumour migration and invasion refocused the
“spotlight” on this pathway [122]. ERK5 (also known as BMK1) is activated by various stimuli such as
oxidative stress, growth factors and oncogenes and plays an important role in cell proliferation, survival,
differentiation and embryonic development of the vascular system [122,123] (Figure 1). The role of
ERK5 in cell proliferation was demonstrated by in vitro expression of a dominant-negative form that
resulted in preventing HeLa cells from entering the S phase of the cell cycle [124]. Similar results
were observed in other cancer cell lines, re-enforcing its role as a regulator of cell proliferation [122].
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ERK5 involvement in cell survival has been shown using in vivo and in vitro experimental approaches.
The inactivation of the MEK5/ERK5 pathways using a mek5´/´ mouse model sensitized the mek5´/´
mouse embryonic fibroblast (MEFs) to osmotic-stress-induced apoptosis [125]. In another model
(mouse tumour xenograft model), the induced deletion of ERK5, significantly reduced tumour volume
and vascular density, that were mediated by the pro-proliferative and pro-survival factors RSK (p90
ribosomal S6 kinase) and rpS6 (ribosomal protein) [126]. In vitro, knockdown of ERK5 using siRNA,
triggered apoptosis and reduced chemo-resistance of HL-60 acute myeloid leukemia cells [126]. ERK5
also appears to play a role in prostate cancer invasion and metastasis. High levels of expression of
ERK5 correlated with the presence of bony metastases and less favourable disease-specific survival in
prostate cancer patients. This expression was associated with increased expression of the extracellular
matrix proteinase MMP9 [127]. The role of ERK5 in controlling cell differentiation has been shown
by its negative control of macrophage differentiation through negative regulation of the expression of
macrophage colony stimulating factor receptor (M-CSFR) [128]. Finally, the role of the ERK5 pathway
in neoangiogenesis has been evidenced by target depletion of ERK5 in xenograft tumour models of
B16F10 melanoma and LL/2 Lewis lung cancer and which resulted in reduced mass and vascular density
of the tumours [126].
The Jun N-terminal kinase (JNK) and the p38 MAPK pathways’ family members, also called
stress activated protein kinase pathways, function in cell context and cell type specific manner [129]
(Figure 1). JNK1, JNK2 and JNK3 are encoded by MAPK8, MAPK9 and MAPK10. Although JNK1
and JNK2 are ubiquitously expressed, JNK3 is mainly expressed in the brain and testis. These factors
mediate their response through targeting AP1, a heterodimeric transcription factor composed of Jun
and Fos family members and which plays an important role in several cellular processes including
proliferation, differentiation and apoptosis. In human cancer, mutations affecting MAPK9 resulted in
JNK1 high expression in liver and prostate cancers, while mutations of MAPK10 that led to a loss of
function was associated with brain tumours [130,131]. Interestingly, in mouse models, the function of
JNK1 and JNK2 in regulating cell proliferation appears to be complex. For instance, mice knockout
experiments of JNK1 and JNK2 resulted in confusing results. JNK1 appears to have a tumor suppressor
function, whereas JNK2 functions as a tumour promoter [132]. Moreover, JNK1 knockout, unlike JNK2,
significantly decreased HCC (hepatocellular carcinoma) in the DEN (diethylnitrosamine)-induced HCC
mouse model [133]. In a similar manner, JNK2 but not JNK1 knockout, prevented skin cancer formation
that was induced by DMBA (7,12-dimethylbenz[a]anthracene) and PMA treatments [134,135]. A
possible explanation to this might be linked to their ability to interact with JUN, a regulator of cell
cycle progression [136]. Finally, higher expression levels of MKK4 and MKK7, two JNK MAP kinase
activators, have been associated with high-grade prostate cancer [132].
The p38 family comprises four isoforms (p38α, p38β, p38γ and p38δ) which could have overlapping
functions [137]. Although p38α is expressed in most tissues, p38β, p38γ and p38δ appear to be
expressed in specific tissues such as the brain, skeletal muscle and endocrine glands [138,139]. The p38
MAPK pathway regulates the phosphorylation of several transcription factors, such as p53, activating
transcription factor 2 (ATF2), ElK1; and protein kinases, including MAPK activated kinase 2 (MK2;
also known as MAPK2), mitogen- and stress-activated protein kinase1 (MsK1), MAP kinase-interacting
serine/threonine kinase 1 (MNK1) and MNK2). This wide spectrum of activities allows the p38 pathway
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to negatively regulate cell cycle progression at the G1/S and G2/M phases of cell cycle progression. This
tumor suppressive role has been studied using mice disrupted in MEK3 and MEK6 genes, where these
mice exhibit increased tumorigenic potential and Ras-induced transformation [140]. Although the p38
MAPK pathway is involved in tumor suppression, increased expression of the phosphorylated form of
p38 correlated with malignancy of different types of cancers [138]. This is consistent with previous
reports that support a role of p38 MAPKs in epithelial-mesenchymal transition (EMT), a key event
associated with cell migration, invasion and tumor cells’ extravasation [140,141]. In contrast, p38 MAPK
pathway appears to play a role in the resistance to anoikis, another important event in tumor migration
and spreading, as it allows cancer cells to survive following a loss of contact with the extracellular
matrix or their neighboring cells [142]. Overall, the p38 MAPK pathway appears to be expressed in
several types of cancers and in this regard constitutes a potential target for cancer therapies.
Targeting the RAS/MAP Kinase Pathway in Cancer
Most of cancer associated mutations affecting the MAP kinase signaling pathway involve mutations
in RAS and RAF genes [143,144]. Mutations in RAS family of genes (K-RAS, N-RAS, H-RAS) have been
found in several types of cancers [145]. High frequency of KRAS mutations are found in pancreatic,
large intestine, biliary tract, small intestine, lung, endometrial and ovarian cancers. High frequencies
of NRAS mutations are associated with melanoma, nervous system, hematopoietic and lymphatic, and
thyroid cancers. HRAS mutations have a high frequency in salivary gland, urinary tract, cervix, upper
aerodigestive tract, penis, prostate and skin cancers.
Mutations associated with RAF family (A-Raf, B-Raf, and C-Raf) are mainly associated with the
BRAF gene and are found in a variety of cancers with high frequency in malignant melanoma, thyroid
and colon carcinoma [146]. This mutation is single-base missense substitution of valine with glutamic
acid at codon 600 (V600E) of the kinase domain and is prevalent in melanomas and papillary thyroid
carcinomas [147,148]. Although low frequency, ARAF mutations are found in ovary and large intestine
tumors and CRAF mutations in ovary and lung tumors [145].
Small inhibitor molecules are being developed to target primarily Mek and Raf in patients with
different types of cancers [145] (Figure 3 and Table 2). Sorafenib, PLX4720, PLX4032 and
GSK2118436 are drugs which are being used to target B-RafV600E in malignant melanoma and other
advanced malignancies. Other chemical inhibitors such as LErafAON (NeoPharm) and ISIS 5132
are being used to target C-Raf in ovarian and breast cancers but also in other malignancies. MEK
inhibitors such as CI-1040, PD-0325901, AZD6244, RDEA119/BAY 86-9766, GDC-0973/XL581 and
AZD8330/ARRY-424704 which are also being tested clinically target MEK and for a wide variety of
cancers, while others such as GSK1120212 target, in addition to MEK, C-Raf, B-Raf V600E and BRAF
wild type [145]. Finally, inhibitors of the JNK proteins are being investigated for potential clinical use.
These include the ATP-competitive JNK inhibitor SP600125 and JNK peptide inhibitor (D-JNKI-1),
which showed promising results in vitro and in vivo tumor models [132] (Figure 3). P38 pathway
inhibitors are mainly developed for treatment of diseases such as rheumatoid arthritis and Crohn’s
disease, however, the inhibitor LY2228820 dimesylate produced significant inhibition of the tumors’
growth in in vivo models of melanoma, NSCLC, glioma, myeloma, and ovarian and breast cancers [149].
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Table 2. Cont.
Target Compound Cancer References
MAP Kinase pathway
C-RAF, MEK
GSK1120212 Various cancers [143–146]B-RAFV600E
BRAF wild type
PI3K/AKT pathway
PI3K/mTOR
NVP-BEZ235
Various cancers [150–164]
BGT226
XL765/SAR245409
SF1126
GDC-0980
PI-103
PF-04691502
PKI-587
GSK2126458
2.3. The PI3K/AKT Pathway
RTKs activation by growth factors, hormones, cytokines, neurotrophic factors and other
extracellular signalling molecules trigger the activation of the lipid kinase PI3K, which
phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) on the plasma membrane and generates
phosphatidylinositol-3,4,5-trisphosphate (PIP3) (Figure 1). The serine/threonine kinase Akt/PKB
binds to PIP3, through its pleckstrin homology (PH) domain resulting in Akt translocation to
the membrane and its partial phosphorylation by the phosphoinositide-dependent protein kinase 1
(PDK1) at Thr308. Akt is fully activated upon its phosphorylation at Ser473 by mTOR complex 2
(mTORC2) [165,166]. Following these series of activations, Akt phosphorylates several target proteins
such as the glycogen synthase kinase 3α(GSK3α), mTOR, forkhead box O transcription factors
(FoxO), MDM2, BCL2-interacting mediator of cell death (BIM) and BCL2-associated agonist of cell
death (BAD), to facilitate cell survival and cell cycle entry [150,167]. Akt activation is negatively
regulated by the Phosphatase and Tensin Homolog (PTEN), which dephosphorylates PIP3 preventing
Akt translocation to the plasma membrane and thereby preventing its activation [150].
Targeting the PI3K/AKT Pathway in Cancer
Genetic mutations and amplifications affecting the different molecules associated with this pathway
have been found in several cancers. The somatic mutation of AKT1 isoform associated with the
substitution of glutamic acid by a lysine at amino acid 17 (E17K) of Akt1 have been reported in human
breast, colorectal, ovarian cancers and squamous cell lung carcinoma [168,169]. This mutation activates
Akt1 by promoting its oncogenic localization to the plasma membrane, which stimulates downstream
signaling resulting in cell transformation. Furthermore, this mutation is also found in AKT3 gene and
results in an oncogenic protein product (Akt3E17K) expressed in melanoma tumors [170]. Mutations in
the catalytically active protein (PIK3CA/p100α) and the regulatory protein (p85α), which form the PI3K
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complex, have been reported in glioblastoma, ovarian, breast, colon, and endometrial cancers [171,172].
Mutations in the tumor suppressor PTEN, which negatively regulates Akt activation, have been reported
in glioblastoma, melanoma, endometrial, prostate, breast and ovarian cancers [150]. These mutations
are diverse and include insertion, substitutions and deletions. Genetic amplifications in PIK3CA, AKT1
and the AKT2 genes have also been reported. Other amplifications in the PIK3CA gene were found in
squamous cell lung carcinoma, head and neck, cervical, gastric, and oesophageal cancers [173–175].
Amplifications in the AKT1 gene were associated with gastric cancer and in AKT2 gene with head and
neck, pancreatic, ovary and breast cancers [173,176–179].
Several small molecule inhibitors of the PI3K/AKT pathway have been developed (Figure 4 and
Table 2). Some of these drugs have a dual inhibitor activity or target a specific component of this
pathway. NVP-BEZ235, BGT226, XL765/SAR245409, SF1126, GDC-0980, PI-103, PF-04691502,
PKI-587, and GSK2126458 have a dual activity toward PI3K and mTOR [153]. These inhibitors, some
of which are being tested clinically, target the isoforms of PI3K and the ATP-binding sites of mTORC1
and mTORC2 [152,153]. Small inhibitor molecules have been developed to target specifically PI3K;
among them XL147, PX866, GDC0941, BKM120, CAL101 (targets p110δ) are at early or late clinical
development for patients with advanced solid tumors and lymphomas [154–160]. Small molecule
inhibitors targeting Akt which include Perifosine, GSK690693, VQD002 and MK2206 are also being
tested clinically [150,160–162]. Finally, OSI027 and AZD8055, which target and inhibit the catalytic
site of mTOR, have shown clinical utility in certain cancers [163,164].
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3. Concluding Remarks
Although significant progress has been made in developing small molecule inhibitors and monoclonal
antibodies that target components of the RTK signaling pathways in cancer, substantial challenges
prevent rapid and efficient therapies. In this regard, an important obstacle remains in the capacity of
cancer cells to adapt to these inhibitors by developing resistance through the emergence of additional
mutations. Therefore, complementary inhibitors have to be developed to overcome this resistance.
A combination of inhibitors which target RTK, components of the MAP kinase (MEK or Raf
inhibitors) or PI3K/AKT may have a better effect in cancer patients’ treatment. Finally, cancers have
heterogeneous populations of cells which may react differently to those inhibitors and might play a role in
chemo-resistance and cancer initiation and progression following chemotherapeutic treatments. Cancer
stem cells are a well-known example of chemo-resistance that leads to relapse in cancer patients. For
instance, malignant melanoma stem cells express the ATP-binding cassette transporter ABCB5 which
plays an important role in drugs efflux, and, thereby, may attenuate the therapeutic efficiency of the
inhibitors used in cancer therapy [180]. Therefore, a better understanding of tumor cellular heterogeneity
would result in better therapeutic design and more efficient drugs.
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